Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Anthracene-9-Carboxylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.95 |
| ▸ | BCHE known ✓ | P06276 | 1/20 | 0.46 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.95 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.95 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.95 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.95 |
| ▸ | HPGD | P15428 | 2/20 | 0.95 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.95 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.95 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.95 |
| ▸ | ME2 | P23368 | 1/20 | 0.49 |
| ▸ | ME1 | P48163 | 1/20 | 0.49 |
| ▸ | ME3 | Q16798 | 1/20 | 0.49 |
| ▸ | CDC25B | P30305 | 3/20 | 0.49 |
| ▸ | LDHA | P00338 | 1/20 | 0.48 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.48 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.48 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anthracene-9-Carboxylic Acid SCHEMBL29352186 | 0.98 | MEN1 (1.00) | MEN1KMT2ACYP1A2ALDH1A1HPGD | |
| Anthracene-9-Carboxylic Acid SCHEMBL122832 | 0.98 | MEN1 (1.00) | MEN1KMT2ACYP1A2ALDH1A1HPGD | |
| Anthracene-9-Carboxylic Acid SCHEMBL11788252 | 0.95 | MEN1 (0.95) | MEN1KMT2ACYP1A2ALDH1A1HPGD | |
| Anthracene-9-Carboxylic Acid SCHEMBL28099540 | 0.95 | MEN1 (0.95) | MEN1KMT2ACYP1A2ALDH1A1HPGD | |
| Anthracene-9-Carboxylic Acid SCHEMBL27733356 | 0.95 | MEN1 (0.95) | MEN1KMT2ACYP1A2ALDH1A1HPGD | |
| Anthracene-9-Carboxylic Acid SCHEMBL28121546 | 0.95 | MEN1 (0.95) | MEN1KMT2ACYP1A2ALDH1A1HPGD | |
| Anthracene-9-Carboxylic Acid SCHEMBL28243282 | 0.93 | MEN1 (0.91) | MEN1KMT2ACYP1A2ALDH1A1HPGD | |
| SCHEMBL4896934 | 0.90 | ALDH1A1 (0.84) | MEN1KMT2ACYP1A2ALDH1A1HPGD | |
| Anthracene-9-Carboxylic Acid SCHEMBL28344339 | 0.88 | KDM4E (0.81) | MEN1KMT2ACYP1A2ALDH1A1HPGD | |
| Anthracene-9-Carboxylic Acid SCHEMBL4342938 | 0.86 | KMT2A (0.78) | MEN1KMT2ACYP1A2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114957156-A | Compound containing benzoxazine structure, resin composition, prepreg and electric copper clad laminate, and preparation method and application thereof | 成都科宜高分子科技有限公司 | 2022-08-30 | — | — | CN | claimed |
| CN-114957156-A | Compound containing benzoxazine structure, resin composition, prepreg and electric copper clad laminate, and preparation method and application thereof | 成都科宜高分子科技有限公司 | 2022-08-30 | — | — | CN | disclosed |
| EP-3216783-B1 | SULFONATE COMPOUND, PHOTOACID GENERATOR, AND PHOTOLITHOGRAPHIC RESIN COMPOSITION | SAN APRO LTD (JP) | 2021-06-09 | — | — | EP | disclosed |
| US-10450266-B2 | Sulfonate compound, photoacid generator, and resin composition for photolithography | SAN-APRO LIMITED (JP) | 2019-10-22 | — | — | US | disclosed |
| EP-3216783-A1 | SULFONATE COMPOUND, PHOTOACID GENERATOR, AND PHOTOLITHOGRAPHIC RESIN COMPOSITION | San-Apro Ltd. (JP) | 2017-09-13 | — | — | EP | disclosed |
| US-20170233336-A1 | SULFONATE COMPOUND, PHOTOACID GENERATOR, AND RESIN COMPOSITION FOR PHOTOLITHOGRAPHY | SAN-APRO LIMITED (JP) | 2017-08-17 | — | — | US | disclosed |
| US-20030036532-A1 | Use of 2-phenylene diamine derivatives for the treatment of infections | JOMAA PHARMAKA GMBH (DE) | 2003-02-20 | — | — | US | disclosed |
| EP-1061956-B1 | MANGANESE CHELATES WITH HIGH RELAXIVITY IN SERUM | BRACCO SPA (IT) | 2002-12-11 | — | — | EP | disclosed |
| US-6337064-B1 | USED AS CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING, MEDICAL DIAGNOSIS | DIBRA S.P.A. (IT) | 2002-01-08 | — | — | US | disclosed |
| EP-1061956-A1 | MANGANESE CHELATES WITH HIGH RELAXIVITY IN SERUM | BRACCO S.p.A. (IT) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999045967-A1 | MANGANESE CHELATES WITH HIGH RELAXIVITY IN SERUM | BRACCO S.P.A. (IT) | 1999-09-16 | — | — | WO | disclosed |
| US-4413052-A | Photopolymerization process employing compounds containing acryloyl group and anthryl group | CIBA-GEIGY CORPORATION (US) | 1983-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030036532-A1 | Use of 2-phenylene diamine derivatives for the treatment of infections | HRH2, ASPH, NQO2 | GLA 3174/4885BCHE 788/4885ACHE 835/4885 |
| US-20170233336-A1 | SULFONATE COMPOUND, PHOTOACID GENERATOR, AND RESIN COMPOSITION FOR PHOTOLITHOGRAPHY | ASIC1, ASIC3, SULT1A1 | GLA 3050/4885BCHE 4792/4885ACHE 4874/4885 |
| US-10450266-B2 | Sulfonate compound, photoacid generator, and resin composition for photolithography | ASIC1, ASIC3, SULT1A1 | GLA 3050/4885BCHE 4792/4885ACHE 4874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.